A global digital biomarkers market is projected to be worth over USD 22 billion by 2030, growing at a CAGR of 35.74%, claims Roots Analysis

Roots Analysis has done a detailed study on “Digital Solutions for Biomarkers Market, 2021-2030” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 270+ page report, which features 135+ figures and 140+ tables, please visit https://www.rootsanalysis.com/reports/digital-biomarkers-market.html

 

Key Market Insights

§  Presently, over 30 players are engaged in the development of digital solutions for different types of biomarkers; these solutions can be analyzed in silico, for a variety of diseases / clinical conditions

§  The pipeline features a variety of digital solutions, which are being evaluated across different stages of development, designed to identify and analyze a diverse set of biomarkers, for use across a range of indications

§  In order to maintain a competitive edge, companies engaged in the development of digital solutions for biomarkers are presently focusing on the integration of advanced features into their respective product offerings

§  In the short to mid-term, considering their applicability across more than 35 target indications, more solutions for physiological / vocal biomarkers are likely to be developed for patient diagnosis / monitoring

§  Case Study: The gradual shift towards incorporation of digital health tools to overcome physical confines of clinical environment is evident from ~40 global events that have recently been organized for digital biomarkers

§  Foreseeing a lucrative future, several public and private investors have made investments worth around USD 1 billion, across over 110 publicly reported funding instances

§  The growing interest of stakeholders is also evident from the rise in partnership activity within this domain; in fact, the maximum number of collaborations related to digital solutions for biomarkers were inked in 2020

§  In order to tap into the lucrative opportunity associated with these modern solutions, several big pharma players have also undertaken diverse initiatives in this field, ranging from product development to strategic investments

§  The market for digital solutions for biomarkers is expected to witness growth at an annualized rate of about 32%, from 2021-2030, with revenues from product sales coming in via both B2B and B2C channels

§  The projected future opportunity for companies engaged in this field is expected to be well distributed across different therapeutic areas, purposes of solutions, and key geographical regions

 

For more information, please visit https://www.rootsanalysis.com/reports/digital-biomarkers-market.html

 

Table of Contents

 

1.         PREFACE                    

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines

 

2.         EXECUTIVE SUMMARY

 

3.         INTRODUCTION

3.1        Chapter Overview

3.2.       Digitization in the Healthcare Sector

3.3.       Next-Generation Healthcare Solutions

 

Chapter Overview

3.2.       Overview of Digital Biomarkers

3.2.1     Classification of Digital Biomarkers                   

3.2.2     Key Advantages and Limitations

 

3.3.       Digital Biomarker-related Product Development and Commercialization Path

3.3.1.    Product Discovery and Development

3.3.2.    Validation and Regulatory Submissions

3.3.3.    Distribution and Marketing

 

3.4.       Prevalent Trends Related to Digital Biomarkers

3.4.1.    Emerging Focus Areas

3.4.2.    Key Historical Trends

3.4.3.    Geographical Activity

 

4.         MARKET LANDSCAPE

4.1.       Chapter Overview

4.2.       Digital Solutions for Biomarkers: Overall Market Landscape

4.2.1.    Analysis by Current Status

4.2.2.    Analysis by Content of Solution

4.2.3.    Analysis by Purpose of Solution

4.2.4.    Analysis by Type of Biomarker

4.2.5.    Analysis by Target Indication(s)

4.2.6.    Analysis by Therapeutic Area

4.2.7.    Analysis by Target Population

4.2.8.    Analysis by Prescription Requirement

 

4.3.       Digital Solutions for Biomarkers: Developer Landscape

4.3.1.    Analysis by Year of Establishment

4.3.2.    Analysis by Company Size

4.3.3.    Analysis by Type of Business Model Used

4.3.4     Analysis by Location of Headquarters

 

4.4.       Leading Developers: Analysis by Number of Digital Solutions for Biomarker

4.5.       Digital Solutions for Biomarkers: Information on Additional Players

 

5.         KEY INSIGHTS

5.1.       Chapter Overview

5.2.       4D Bubble Analysis: Analysis by Portfolio Strength, Type of Biomarker and Company Size

5.3.       Grid Representation: Analysis by Current Status, Content of Solution and Therapeutic Area

5.4.       Treemap Representation: Analysis by Therapeutic Area and Company Size

5.5.       World Map Representation: Analysis by Location of Headquarters

5.6.       Current and Future Market Landscape Trends Analysis

 

6.         COMPANY PROFILES

6.1.       Chapter Overview

6.2.       Acculi Labs

6.2.1     Company Overview

6.2.2.    Product Portfolio

6.2.3.    Recent Developments and Future Outlook

 

6.3.       Canary Health Technologies

6.3.1.    Company Overview

6.3.2.    Product Portfolio

6.3.3.    Recent Developments and Future Outlook

 

6.4.       Empatica

6.4.1.    Company Overview

6.4.2.    Product Portfolio

6.4.3.    Recent Developments and Future Outlook

 

6.5        IXICO

6.5.1.    Company Overview

6.5.2.    Product Portfolio

6.5.3.    Recent Developments and Future Outlook         

 

6.6.       Kinsa

6.6.1.    Company Overview

6.6.2.    Product Portfolio

6.6.3.    Recent Developments and Future Outlook

 

6.7.       Progentec Diagnostics

6.7.1.    Company Overview

6.7.2.    Product Portfolio

6.7.3.    Recent Developments and Future Outlook         

 

6.8.       Vocalis Health

6.8.1.    Company Overview

6.8.2.    Product Portfolio

6.8.3     Recent Developments and Future Outlook

 

7.         PRODUCT COMPETITIVENESS ANALYSIS

7.1.       Chapter Overview

7.2.       Key Parameters and Methodology

7.3.       Product Competitiveness Analysis

7.3.1.    Product Competitiveness Analysis: Idiosyncratic Biomarkers

7.3.2.    Product Competitiveness Analysis: Physiological Biomarkers

7.3.3.    Product Competitiveness Analysis: Vocal Biomarkers

7.3.4.    Product Competitiveness Analysis: Other Biomarkers

 

8.         GLOBAL EVENTS ANALYSIS

8.1.       Chapter Overview

8.2.       Scope and Methodology

 

8.3.       Global Events Related to Digital Biomarkers

8.3.1.    Analysis by Year of Occurrence

8.3.2.    Analysis by Event Platform

8.3.3.    Analysis by Geography

8.3.4.    Analysis by Type of Event

8.3.5.    Evolutionary Trend in Key Agenda / Event Agenda

8.3.6.    Most Active Event Organizers

8.3.7.    Most Active Players in Terms of Event Participation

8.3.8.    Analysis by Seniority Level of Participants

 

9.         FUNDING AND INVESTMENT ANALYSIS

9.1.       Chapter Overview

9.2.       Types of Funding

 

9.3.       Digital Solutions for Biomarkers: Funding and Investment Analysis

9.3.1.    Analysis by Number of Funding Instances

9.3.2.    Analysis by Amount Invested

9.3.3.    Analysis by Type of Funding

9.3.4.    Analysis by Type of Biomarker

9.3.5.    Analysis by Therapeutic Area

9.3.6.    Analysis by Geography

9.3.7.    Most Active Players: Analysis by Number of Instances

9.3.8.    Most Active Players: Analysis by Amount Invested

9.3.9.    Most Active Investors: Analysis by Number of Instances

                       

9.4        Concluding Remarks

 

10.        PARTNERSHIPS AND COLLABORATIONS

10.1.     Chapter Overview

10.2.     Partnership Models

 

10.3.     Digital Solutions for Biomarkers: Recent Partnerships and Collaborations

10.3.1.  Analysis by Year of Partnership

10.3.2.  Analysis by Type of Partnership

10.3.2.1 Analysis by Type of Partnership and Year of Partnership

10.3.2.2 Analysis by Type of Partnership and Company Size

 

10.3.3.  Analysis by Type of Partner

10.3.3.1. Analysis by Type of Partner and Year of Partnership

10.3.3.2. Analysis by Type of Partner and Type of Partnership

10.3.3.3. Analysis by Type of Partner and Company Size

 

10.3.4.  Analysis by Type of Biomarker

10.3.4.1. Analysis by Type of Biomarker and Year of Partnership

10.3.4.2. Analysis by Type of Biomarker and Type of Partnership

 

10.3.5.  Analysis by Therapeutic Area

10.3.5.1. Analysis by Therapeutic Area and Year of Partnership

10.3.5.2. Analysis by Therapeutic Area and Type of Partner

 

10.3.6.  Most Active Players: Analysis by Number of Partnerships

10.3.7.  Regional Analysis

10.3.8.  Intercontinental and Intracontinental Agreements

 

11.        BIG PHARMA INITIATIVES

11.1.     Chapter Overview

11.2.     Scope and Methodology

 

11.3.     Digital Biomarker-related Initiatives of Big Pharma Players

11.3.1.  Clinical Research Activity

11.3.2.  Partnership Activity

11.3.3.  Funding and Investments

11.3.4.  Participation in Global Events

11.3.5.  Research Publications

 

11.4.     Benchmark Analysis of Big Pharmaceutical Players

11.4.1.  Spider Web Analysis: Company A

11.4.2.  Spider Web Analysis: Company B

11.4.3.  Spider Web Analysis: Company C

11.4.4.  Spider Web Analysis: Company D

11.4.5.  Spider Web Analysis: Company E

11.4.6.  Spider Web Analysis: Company F

11.4.8.  Spider Web Analysis: Company G

11.4.8.  Spider Web Analysis: Company H

11.4.9.  Spider Web Analysis: Company I

11.4.10. Spider Web Analysis: Company J

11.4.11. Spider Web Analysis: Company K

11.4.12. Spider Web Analysis: Company L

11.4.13. Spider Web Analysis: Company M

 

12.        MARKET FORECAST

12.1.     Chapter Overview

12.2.     Forecast Methodology and Key Assumptions

12.3.     Digital Solutions for Biomarkers Market, 2021-2030

 

12.4.     Digital Solutions for Biomarkers Market: Distribution by Content of Solution

12.4.1. Digital Solutions for Biomarkers Market for Standalone Software Applications, 2021-2030

12.4.2. Digital Solutions for Biomarkers Market for Combination Offering (Software Application + AI Support), 2021-2030

12.4.3. Digital Solutions for Biomarkers Market for Combination Offering (Software Application + Device), 2021-2030

12.4.4. Digital Solutions for Biomarkers Market for Combination Offering (Software Application + AI Support + Device), 2021-2030

12.4.5. Digital Solutions for Biomarkers Market for Other Content of Solutions, 2021-2030

 

12.5.     Digital Solutions for Biomarkers Market: Distribution by Purpose of Solution

12.5.1. Digital Solutions for Biomarkers Market for Diagnosis, 2021-2030

12.5.2. Digital Solutions for Biomarkers Market for Early Screening, 2021-2030

12.5.3. Digital Solutions for Biomarkers Market for Monitoring, 2021-2030

12.5.4. Digital Solutions for Biomarkers Market for Predictive Insights, 2021-2030

 

12.6.     Digital Solutions for Biomarkers Market: Distribution by Type of Biomarker

12.6.1. Digital Solutions for Cognitive Biomarkers Market, 2021-2030

12.6.2. Digital Solutions for Idiosyncratic Biomarkers Market, 2021-2030

12.6.3. Digital Solutions for Physiological Biomarkers Market, 2021-2030

12.6.4. Digital Solutions for Vocal Biomarkers Market, 2021-2030

12.6.5. Digital Solutions for Other Biomarkers Market, 2021-2030

 

12.7.     Digital Solutions for Biomarkers Market: Distribution by Therapeutic Area

12.7.1. Digital Solutions for Biomarkers Market for Autoimmune Disorders, 2021-2030

12.7.2. Digital Solutions for Biomarkers Market for Cardiovascular Disorders, 2021-2030

12.7.3. Digital Solutions for Biomarkers Market for Infectious Disorders, 2021-2030

12.7.4. Digital Solutions for Biomarkers Market for Mental Health Problems, 2021-2030

12.7.5. Digital Solutions for Biomarkers Market for Neurological Disorders, 2021-2030

12.7.6. Digital Solutions for Biomarkers Market for Respiratory Disorders, 2021-2030

12.7.7. Digital Solutions for Biomarkers Market for Substance Use Disorders, 2021-2030

12.7.8. Digital Solutions for Biomarkers Market for Other Disorders, 2021-2030

 

12.8.     Digital Solutions for Biomarkers Market: Distribution by Business Model

12.8.1. Digital Solutions for Biomarkers Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2021-2030

12.8.2. Digital Solutions for Biomarkers Market for B2C Model (Patients and Caregivers), 2021-2030

 

12.9.     Digital Solutions for Biomarkers Market: Distribution by Key Geographical Regions

12.9.1. Digital Solutions for Biomarkers Market in North America, 2021-2030

12.9.2.  Digital Solutions for Biomarkers Market in Europe, 2021-2030

12.9.3. Digital Solutions for Biomarkers Market in Asia-Pacific, 2021-2030

12.9.4. Digital Solutions for Biomarkers Market in Middle East and North Africa (MENA), 2021-2030

12.9.5. Digital Solutions for Biomarkers Market in Rest of the World, 2021-2030

 

12.10.   Concluding Remarks

 

13.        IMPACT OF COVID-19 PANDEMIC ON DIGITAL SOLUTIONS FOR                  BIOMARKERS MARKET

13.1.     Chapter Overview

13.2.     Impact of COVID-19 Pandemic on Digital Solutions for Biomarkers Market

13.2.1.  Impact on Future Market Opportunity for Digital Solutions for Biomarkers 

13.3.     Current Opinions and Key Initiatives of Key Players

 

13.4.     Recuperative Strategies for Developer Businesses

13.4.1.  Strategies for Implementation in the Short / Mid Term

13.4.2.  Strategies for Implementation in the Long Term

 

14.        CONCLUSION

14.1.     Chapter Overview

14.2.     Key Takeaways

 

15.        EXECUTIVE INSIGHTS

15.1.     Chapter Overview

15.2.     Tilak Healthcare

15.2.1.  Company Snapshot

15.2.2.  Interview Transcript: Edouard Gasser, Co-Founder and Chief Executive Officer

 

15.3.     Vocalis Health

15.3.1.  Company Snapshot

15.3.2.  Interview Transcript: Michael Seggev, Chief Commercial Officer

 

16.        APPENDIX I: TABULATED DATA

 

17.        APPENDIX II: LIST OF COMPANIES AND ORGANIZATION

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com